^
Association details:
| Biomarker: | FLT3-ITD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Reolysin (pelareorep) (Apoptosis stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The Clinical Oncolytic Reovirus Formulation Reolysin Synergistically Augments the Anti-Leukemic Activity of Azacitidine
Published date:
11/04/2021
Excerpt:
Finally, Reolysin (5 x 108 TCID50 IV 1x per week), azacitidine (5 mg/kg SC 2x per week), and the combination were administered to mice bearing MOLM-13 FLT3-ITD+ xenografts for 19 days to assess the efficacy and tolerability of each treatment. Combination treatment was well tolerated and antagonized disease progression significantly more effectively than either monotherapy (p<0.01).
Secondary therapy:
azacitidine
DOI:
10.1182/blood-2021-151575
